Companies › Aligos Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALG-000184 Nucleotide reverse transcriptase inhibitor (NrtI) | – | Phase 2 | Chronic Hepatitis B Infection; Healthy Volunteer | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06672900 | ALG-000184 | Phase 1 | Healthy Volunteer | Other | Jul 2025 |
| NCT06963710 | ALG-000184 | Phase 2 | Chronic Hepatitis B Infection | Infectious disease | Mar 2027 |
Cash and short-term investments of $31m on 2026-09-30; operating cash outflow about $63m a year; runway about 6 months at that burn, to Mar 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Freya Biosciences ApS Avenue Therapeutics BioAegis Therapeutics Lakewood-Amedex 60 Degrees Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.